Mutations in other genes such as KRAS proto-oncogene GTPase (KRAS), tumor protein p53 (TP53), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) are also reported in NSCLC, with co-existing mutations implicating lower progression free survival (PFS) [21]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.